Personalized mRNA vaccine induces strong, durable immunity in hard-to-treat breast cancer
In an experimental trial, a personalized mRNA vaccine was tested in 14 individuals with an aggressive form of breast cancer. It trained immune cells to target cancer-specific mutant proteins, inducing strong, lasting immunity. Ten participants remained disease-free. Analysis of relapses revealed resistance mechanisms, offering essential insights for future therapies. T cells targeting cancer-specific mutant proteins remained in treated individuals years after vaccination.
Publication Details
- Journal
- Nature
- Published
- 2026-02-18
- DOI
- https://doi.org/10.1038/d41586-026-00477-0
- Primary Topic
- Immune responses and vaccinations
- Type
- article
- Field-Weighted Citation Impact
- 0.00